We are live on ! Find out more

Arcus Biosciences

RCUS

Market cap $3.98B

31.26 USD

+1.14

3.78%

At close Updated Aug 25, 11:34 AM EDT

1 day

3.78%

5 days

2.69%

1 month

12.28%

3 months

29.55%

6 months

54.22%

Year to date

34.22%

1 year

207.98%

5 years

6.15%

10 years

83.88%

About: Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

Employees: 601

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 22.7%

Neutral 72.7%

Negative 4.5%

Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm

NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Arcus Biosciences, Inc. ( NYSE : RCUS) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.

Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 2,850 shares of the Company's common stock at an exercise price per share of $28.72, which was the.

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Q2 Earnings Call Highlights

Arcus Biosciences NYSE: RCUS outlined plans to expand development of its casdatifan cancer program across multiple lines of clear cell renal cell carcinoma, or ccRCC, while reporting second-quarter financial results and updates on its pancreatic cancer and immunology pipelines.

Arcus Biosciences Q2 Earnings Call Highlights

Arcus Biosciences, Inc. (RCUS) Q2 2026 Earnings Call Transcript

Arcus Biosciences, Inc. (RCUS) Q2 2026 Earnings Call Transcript

Arcus Biosciences, Inc. (RCUS) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates

Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to break-even earnings per share a year ago.

Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates

Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a pipeline update on its clinical-stage investigational molecules and discovery programs. "Our recent publication in Nature demonstrated our commitme.

Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update

Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Arcus Biosciences, Inc. ( NYSE : RCUS) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.

Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 12,600 shares of the Company's common stock at an exercise price per share of $29.73, which was.

Arcus Biosciences Announces New Employment Inducement Grants

Arcus: 'Buy' On Casdatifan Late-Stage CcRCC Advancement And 1st-Line Expansions

I initiate Arcus Biosciences with a 'Buy' rating, citing late-stage pipeline catalysts and a strong financial runway. The company's lead asset, casdatifan, is advancing in phase 3 PEAK-1 for 2nd-line ccRCC, with enrollment completion expected by the end of 2026. Expansion into 1st-line ccRCC with casdatifan-based TKI-free regimens and multiple upcoming data readouts offers significant upside potential.

Arcus: 'Buy' On Casdatifan Late-Stage CcRCC Advancement And 1st-Line Expansions

Zacks Investment Research

SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study

Summit announces updated HARMONi overall survival data and partners with Arcus to test ivonescimab in kidney cancer, expanding its late-stage development.

SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study

See News Rankings

Price charts implemented using Lightweight Charts™